| 2025 |
Safaroghli-azar, A., Mekonnen, L. B., Hassankhani, R., Lenjisa, J., Basnet, S. K. C., Batayneh, H., . . . Wang, S. (2025). A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. Investigational New Drugs, 43(3), 728-741.
DOI |
| 2025 |
Mekonnen, L. B., Teo, T., Noll, B., Rahaman, M. H., Lenjisa, J., Basnet, S., . . . Wang, S. (2025). A brain-penetrant CDK4/6 inhibitor - AU3-14 shows robust anti-tumor efficacy against glioblastoma.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 189(118340), 118340.
DOI Europe PMC1 |
| 2024 |
Abdalla-Aslan, R., Bonomo, P., Keefe, D., Blijlevens, N., Cao, K., Cheung, Y. T., . . . Nagano, C. (2024). Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. eClinicalMedicine, 73(102675), 102675-1-102675-12.
DOI Scopus8 WoS9 Europe PMC7 |
| 2024 |
Kasirzadeh, S., Lenjisa, J. L., & Wang, S. (2024). Targeting CDK2 to combat drug resistance in cancer therapy. Future Oncology, 20(39), 3325-3341.
DOI Scopus6 WoS7 Europe PMC5 |
| 2023 |
Fanta, B. S., Mekonnen, L., Basnet, S. K. C., Teo, T., Lenjisa, J., Khair, N. Z., . . . Wang, S. (2023). 2-Anilino-4-(1-methyl-1H-pyrazol-4-yl)pyrimidine-derived CDK2 inhibitors as anticancer agents: Design, synthesis & evaluation. Bioorganic and Medicinal Chemistry, 80(117158), 117158.
DOI Scopus15 WoS15 Europe PMC10 |
| 2023 |
Safaroghli Azar, A., Emadi, F., Lenjisa, J., Mekonnen, L., & Wang, S. (2023). Kinase inhibitors: opportunities for small molecule anticancer immunotherapies. Drug Discovery Today, 28(5), 1-12.
DOI Scopus3 WoS4 Europe PMC1 |
| 2023 |
Fanta, B. S., Lenjisa, J., Teo, T., Kou, L., Mekonnen, L., Yang, Y., . . . Wang, S. (2023). Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation. Molecules, 28(7), 2951.
DOI Scopus7 WoS6 Europe PMC4 |
| 2022 |
Anshabo, A. T., Bantie, L., Diab, S., Lenjisa, J., Kebede, A., Long, Y., . . . Wang, S. (2022). An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 14(5), 1113.
DOI Scopus12 WoS10 Europe PMC10 |
| 2020 |
Bantie, L., Tadesse, S., Likisa, J., Yu, M., Noll, B., Heinemann, G., . . . Wang, S. (2020). A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.. Gynecol Oncol, 159(3), 827-838.
DOI Scopus16 WoS18 Europe PMC16 |
| 2019 |
Khair, N. Z., Lenjisa, J. L., Tadesse, S., Kumarasiri, M., Basnet, S. K. C., Mekonnen, L. B., . . . Wang, S. (2019). Discovery of CDK5 inhibitors through structure-guided approach. ACS, 10(5), 786-791.
DOI Scopus23 WoS21 Europe PMC18 |
| 2017 |
Tadesse, S., Zhu, G., Mekonnen, L. B., Lenjisa, J. L., Yu, M., Brown, M. P., & Wang, S. (2017). A novel series of N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. Future Medicinal Chemistry, 9(13), 1495-1506.
DOI Scopus16 WoS16 Europe PMC11 |
| 2017 |
Lenjisa, J. L., Tadesse, S., Khair, N. Z., Kumarasiri, M., Yu, M., Albrecht, H., . . . Wang, S. (2017). CDK5 in oncology: recent advances and future prospects.. Future medicinal chemistry, 9(16), 1939-1962.
DOI Scopus36 WoS35 Europe PMC32 |
| 2015 |
Lenjisa, J. L., Wega, S. S., Lema, T. B., & Ayana, G. A. (2015). Outcomes of highly active antiretroviral therapy and its predictors: a cohort study focusing on tuberculosis co-infection in South West Ethiopia. BMC Research Notes, 8(1), 446.
DOI Scopus4 Europe PMC2 |
| 2014 |
Lenjisa, J. L., Woldu, M. A., & Satessa, G. D. (2014). New hope for eradication of HIV from the body: The role of polymeric nanomedicines in HIV/AIDS pharmacotherapy. Journal of Nanobiotechnology, 12(1), 9.
DOI Scopus25 Europe PMC13 |
